ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2021
A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- The Effect of Anti-Inflammatory Drugs on the Incidence of Colorectal Cancer.Pharmaceutics · 2026Review
- Transvaginal ultrasound-detected endometrial echogenicity heterogeneity in diagnosing endometrial carcinoma: risk factors and nomogram-based prediction model.Frontiers in oncology · 2026Article
- Transcriptome-wide Mendelian randomization and single-cell analysis during CD4NPJ precision oncology · 2025Article
- Multi-omics analysis identifies diagnostic circulating biomarkers and potential therapeutic targets, revealing IQGAP1 as an oncogene in gastric cancer.NPJ precision oncology · 2025Article
- Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study.BMC gastroenterology · 2025Article
- Global research trends and hotspots in aspirin studies (2014-2024): a bibliometric perspective.Frontiers in pharmacology · 2025Review
- Drug Repurposing for Cancer Treatment: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Mendelian randomisation analysis for intestinal disease: achievement and future.eGastroenterology · 2024Review
- Effects of aspirin on colon cancer using quantitative proteomic analysis.Cancer pathogenesis and therapy · 2024Article
- Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against.British journal of cancer · 2024Article
- Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition.Cancer & metabolism · 2023Article
- Aspirin and cancer: biological mechanisms and clinical outcomes.Open biology · 2022Review
- Identification of novel drug targets for Alzheimer's disease by integrating genetics and proteomes from brain and blood.Molecular psychiatry · 2021Article
- Article
- Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".Journal of cancer research and clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors at 20 institutions in 13 countries.
Aayah NounuMedical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom. an0435@bristol.ac.uk.ORCID 0000-0002-3579-1864
Alexander GreenhoughSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-8306-811X
Kate J HeesomProteomics Facility, Faculty of Life Sciences, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-5418-5392
Rebecca C RichmondMedical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Jie ZhengMedical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Stephanie J WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-3834-1535
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
John A BaronDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.ORCID 0000-0003-3461-1056
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Jane C FigueiredoDepartment of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Noralane M LindorDepartment of Health Science Research, Mayo Clinic, Scottsdale, Arizona.
Graham CaseyCenter for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Elizabeth A PlatzDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.ORCID 0000-0003-3676-8954
Loïc Le MarchandUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Cornelia M UlrichHuntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
Christopher I LiPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Fränzel J B van DuijnhovenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, the Netherlands.ORCID 0000-0001-8367-2352
Andrea GsurInstitute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-9795-1528
Peter T CampbellBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.
Víctor MorenoOncology Data Analytics Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487
Pavel VodickaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
Ludmila VodickovaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-6129-1572
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0001-8919-1971
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-8307-3197
Lori C SakodaPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-0900-5735
Martha L SlatteryDepartment of Internal Medicine, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1655-6543
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-7153-2766
Marc J GunterNutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon, France.
Sergi Castellví-BelGastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain.ORCID 0000-0003-1217-5097
Hyeong Rok KimDepartment of Surgery, Chonnam National University Hwasun Hospital and Medical School, Hwasun, Korea.
Sun-Seog KweonDepartment of Preventive Medicine, Chonnam National University Medical School, Gwangju, Korea.ORCID 0000-0003-2378-8550
Andrew T ChanDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Li LiDepartment of Family Medicine, University of Virginia, Charlottesville, Virginia.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, Tennessee.
D Timothy BishopLeeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom.ORCID 0000-0002-8752-8785
Daniel D BuchananColorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-2225-6675
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0003-4946-9099
Stephen B GruberDepartment of Preventive Medicine & USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-8656-7822
Gad RennertDepartment of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Tabitha A HarrisonPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-4173-7530
Yi LinPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Temitope O KekuCenter for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina.
Michael O WoodsDiscipline of Genetics, Memorial University of Newfoundland, St. John's, Canada.ORCID 0000-0001-8180-418X
Clemens SchafmayerDepartment of General Surgery, University Hospital Rostock, Rostock, Germany.
Bethany Van GuelpenDepartment of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-9692-101X
Steven GallingerLunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Heather HampelDivision of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.ORCID 0000-0001-7558-9794
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Paul D P PharoahDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.ORCID 0000-0001-8494-732X
Annika LindblomDepartment of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7387-6845
Anna H WuUniversity of Southern California, Preventative Medicine, Los Angeles, California.
Emily WhitePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
David A DrewMassachusetts General Hospital and Harvard Medical School, Clinical and Translational Epidemiology Unit, Boston, Massachusetts.ORCID 0000-0002-8813-0816
Dominique SchererInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.ORCID 0000-0003-4430-296X
Justo Lorenzo BermejoInstitute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Ann C WilliamsSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.
Caroline L ReltonMedical Research Council (MRC) Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Bristol City Council · GBFred Hutch Cancer Center · USNational Cancer Institute · USUniversity of Southern California · USUniversity of Washington · USCzech Academy of Sciences · CZGerman Cancer Research Center · DEUniversity of Bristol · GBUniversity of North Carolina at Chapel Hill · USUniversity of Virginia · USZimmer Biomet (Netherlands) · NLAmerican Cancer Society · USBellvitge University Hospital · ESBroad Institute · USCancer Center of Hawaii · USCancer Council Victoria · AUCentre international de recherche sur le cancer · FRCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESChonnam National University · KRChonnam National University Hwasun Hospital · KR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTranslational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MTranslational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MSWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MStatistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8MValidity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI WILLETT, WALTER C. · 1991 to 2009
$41.8MUnderstanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MPILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBERT S. SANDLER · 1985 to 2026
$30.5MCancer Research UK 11975Cancer Research UK 16561Cancer Research UK 19167Cancer Research UK 19169Cancer Research UK 29019Cancer Research UK C18281/A19169Intramural NIH HHS Z01 CP010200Medical Research Council G1000143Medical Research Council MC_UU_00011/4Medical Research Council MC_UU_12013/2Medical Research Council MC_UU_12013_2Medical Research Council MR/R017247/1NCATS NIH HHS KL2 TR000421NCI NIH HHS K05 CA152715NCI NIH HHS K05 CA154337NCI NIH HHS K07 CA190673NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA055075NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA006973NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA066635NCI NIH HHS R01 CA067941NCI NIH HHS R01 CA072520NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA081488NCI NIH HHS R01 CA097325NCI NIH HHS R01 CA136726NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA151993NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA197350NCI NIH HHS R01 CA201407NCI NIH HHS R01 CA207371NCI NIH HHS R03 CA153323NCI NIH HHS R21 CA191312NCI NIH HHS R35 CA197735NCI NIH HHS R37 CA054281NCI NIH HHS U01 CA067941NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA084968NCI NIH HHS U01 CA086308NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA167551NCI NIH HHS U01 CA167552NCI NIH HHS U01 CA206110NCI NIH HHS U10 CA037429NCI NIH HHS U19 CA148107NCI NIH HHS U24 CA074783NCI NIH HHS U24 CA074794NCI NIH HHS UM1 CA167552NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA186107NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS HHSN268201200008CNHLBI NIH HHS HHSN268201200008INHLBI NIH HHS HHSN268201700006CNIA NIH HHS HHSN271201100004CNIA NIH HHS U01 AG018033NIDDK NIH HHS P30 DK034987NIEHS NIH HHS T32 ES013678NIH HHS S10 OD028685Wellcome TrustWellcome Trust 217487/Z/19/ZWHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004CWorld Health Organization 001
Abstract
backgroundEvidence for aspirin's chemopreventative properties on colorectal cancer (CRC) is substantial, but its mechanism of action is not well-understood. We combined a proteomic approach with Mendelian randomization (MR) to identify possible new aspirin targets that decrease CRC risk.
methodsHuman colorectal adenoma cells (RG/C2) were treated with aspirin (24 hours) and a stable isotope labeling with amino acids in cell culture (SILAC) based proteomics approach identified altered protein expression. Protein quantitative trait loci (pQTLs) from INTERVAL (
resultsAltered expression was detected for 125/5886 proteins. Of these, aspirin decreased MCM6, RRM2, and ARFIP2 expression, and MR analysis showed that a standard deviation increase in mRNA/protein expression was associated with increased CRC risk (OR: 1.08, 95% CI, 1.03-1.13; OR: 3.33, 95% CI, 2.46-4.50; and OR: 1.15, 95% CI, 1.02-1.29, respectively).
conclusionsMCM6 and RRM2 are involved in DNA repair whereby reduced expression may lead to increased DNA aberrations and ultimately cancer cell death, whereas ARFIP2 is involved in actin cytoskeletal regulation, indicating a possible role in aspirin's reduction of metastasis. IMPACT: Our approach has shown how laboratory experiments and population-based approaches can combine to identify aspirin-targeted proteins possibly affecting CRC risk.
Indexed as
AspirinColorectal NeoplasmsHumansMendelian Randomization AnalysisProteomicsRisk FactorsAspirin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02328677ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.